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ABSTRACT Knowledge Management (KM) is a key enabler
for achieving quality in a lifecycle approach for production of
biopharmaceuticals. Due to the important role that it plays
towards successful implementation of Quality by Design
(QbD), an analysis of KM solutions is needed. This work pro-
vides a comprehensive review of the interface betweenKM and
QbD-driven biopharmaceutical production systems as per-
ceived by academic as well as industrial viewpoints. A compre-
hensive set of 356 publications addressing the applications of
KM tools to QbD-related tasks were screened and a query to
gather industrial inputs from 17 major biopharmaceutical or-
ganizations was performed. Three KM tool classes were iden-
tified as having high relevance for biopharmaceutical produc-
tion systems and have been further explored: knowledge indi-
cators, ontologies, and process modeling. A proposed categori-
zation of 16 distinct KM tool classes allowed for the identifica-
tion of holistic technologies supporting QbD. In addition, the
classification allowed for addressing the disparity between in-
dustrial and academic expectations regarding the application of
KMmethodologies. This is a first of a kind attempt and thus we
think that this paper would be of considerable interest to those
in academia and industry that are engaged in accelerating de-
velopment and commercialization of biopharmaceuticals.
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management . ontologies . process modeling . quality by design
ABBREVIATIONS
CPP Critical process parameters
CQA Critical quality attributes
ICH International conference on harmonisation of techni-
cal requirements for registration of pharmaceuticals
for human use
KM Knowledge management
PAT Process analytical technologies
QbD Quality by design
RM Risk management
INTRODUCTION
Relevance of Knowledge Management
for Pharmaceutical Quality Systems
Quality by Design (QbD) has been defined in the ICH Q8
guideline as Ba systematic approach to development that begins
with predefined objectives and emphasizes product and process
understanding and process control, based on sound science and
quality risk management^ (1,2). This is a science and risk based
approach of product development and includes steps of identi-
fication of the product attributes that are of significant impor-
tance to the product’s safety and/or efficacy (Quality Target
Product Profile and Critical Quality Attributes); design of the
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process to deliver these attributes; a robust control strategy to
ensure consistent process performance; validation and filing of
the process demonstrating the effectiveness of the control strat-
egy; and finally ongoing monitoring to ensure robust process
performance over the life cycle of the product (Fig. 1).
Knowledge management can play a key role in facilitating
efficient transfer and utilization of information to facilitate the
above mentioned tasks. For example, a major task in
implementing Quality by Design (QbD) is to holistically review
knowledge coming from a disparate variety of sources and then
use it to assess criticality of the various quality attributes (1,2). It
is unlikely that the manufacturer has specific information about
each and every attribute for a given biotherapeutic to assess its
criticality. Most likely, the manufacturer will be making a deci-
sion based on what has been reported in literature and prior
experience with other similar product. Further, QbD necessi-
tates that knowledge gained over a product’s lifecycle can be
utilized in an environment of continuous improvement (1,2).
Data generated during a life-cycle can be used to start QbD
for the next product and/or create an ‘improved’ product.
With the widespread adoption of QbD principles by the bio-
pharmaceutical industry, and the growing emphasis on en-
hanced process understanding, the need for establishing effi-
cient KM strategies is more than ever (3). KM can be quite
effective in managing the flow of information towards develop-
ment of design space, control strategies, and technology transfer
as well as use this information towards continuous improve-
ment of the process and the product (4).
Within this context, the International Conference on
Harmonization (ICH) defines Knowledge Management
(KM) as Ba systematic approach to acquiring, analyzing, stor-
ing and disseminating information related to products,
manufacturing processes and components^ (5). In the field of
biotechnology, this definition can be interpreted as consisting
of capturing, structuring, retaining and reusing information in
order to understand a particular biological system and to de-
liver the gained knowledge to an information system (6,7). The
information system should ideally be able to capture the rele-
vant knowledge, deliver it to the relevant user, and invest it to
improve organizational and/or individual performance (8).
Classification of Knowledge Management Tools
To clarify the prevalence of different KM tools in the academ-
ic literature and their perceived industrial relevance, a classi-
fication of KM tools based on functionality is needed. KM
tools can be arranged inside the four basic dimensions pro-
posed in the ICH guidelines: acquisition, analysis, storage and
dissemination (Table I), similar to previous efforts (41–43).
The ICH Q8 guideline makes reference to the need for KM
in the form of BThe information and knowledge gained from
pharmaceutical development studies and manufacturing ex-
perience provide scientific understanding to support the estab-
lishment of the design space, specifications, and manufactur-
ing controls^ and BChanges in formulation and manufactur-
ing processes during development and lifecycle management
should be looked upon as opportunities to gain additional
knowledge and further support establishment of the design
space^ (44). Similarly, ICHQ9 discusses the role of knowledge
in assessing risk as well as in activities such as change control
Fig. 1 Illustration showing the link
between the various sources of
knowledge and QbD applications
by knowledge management
functions. Knowledge flow starts
from the four possible sources and
may consist of symbols (numbers,
letters), data (collections of
symbols), information (data in
context), and knowledge (applied
information). KM uses four
distinctive functions to efficiently
guide the flow of knowledge
towards achieving QbD goals as
required to gain product and
process understanding.
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(45). In an earlier publication, we identified a set of 12 KM
tools commonly applied by pharmaceutical organizations
throughout their products’ lifecycle (7). Since it is necessary
to involve strategy, organizational culture, and cooperation
between departments in any KM system (46), in this work,
we expanded the classification by an additional supporting
dimension consisting of four tools: KM models, strategies,
indicators, and frameworks.
Analyzing Knowledge Within Pharmaceutical Systems
The use of KM tools in biopharmaceutical production systems
can further be organized by the type of knowledge being an-
alyzed and the specific QbD activities addressed. According to
the relevant ICH guidelines (Q8–Q11) and the forthcoming
Q12 guideline about lifecycle management, several knowl-
edge sources typically need to be accounted for, including
prior knowledge, pharmaceutical development studies, tech-
nology transfer activities and manufacturing experience
(5,44,45,47,48). Therefore, each application of KM tools
can be based on these four different classes of knowledge
sources as shown in Fig. 1. In addition, it is necessary to have
the final destination of the knowledge flow inmind. The use of
each KM tool can be studied based on the specific QbD ac-
tivities addressed, primordially: design space establishment,
risk management, development of control strategies, and iden-
tification of CQAs. In addition, since many literature sources
do not directly link the application of tools to specific QbD
issues, general categories that are frequently used to describe
KM benefits, such as manufacturing facilitation, enhance-
ment of body of knowledge, regulatory flexibility, and innova-
tion support have been introduced.
METHODOLOGY
To gain insights about the status of various KM tools within
the academic literature, an exhaustive non-systematic litera-
ture review was conducted according to a defined protocol
(available in the Supplementary Information section). The
following databases were searched: ScienceDirect (search
date: 02.11.14), Embase (search date: 02.11.14), IEEE (search
date: 02.11.14), Scopus (search date: 06.11.14), Springer
(search date: 20.11.14) and Taylor & Francis (search date:
02.11.14). All publications that contained the term
BKnowledge Management^ in combination with the words
Bpharmaceutical,^ Bbiotechnological,^ Bdrugs^ or Bchemical^
were selected.
With this search strategy, a total of 5203 records were
found after removing duplicates, without employing any other
kind of information source or contacting authors for further
information. A manual selection was performed to assure that
the studies were fitting into the framework for pharmaceutical
development and quality systems within the QbD approach.
This was done in the first instance by reading each of the
paper’s titles and discarding all of those that did not fit into
the pharmaceutical, chemical or biotechnological sectors or
that did not correspond to the title of a research paper; in
some cases, this screening was supported with the analysis of
the paper’s abstracts. In the second instance, those records
that through the analysis of their abstracts could not be fitted
within the scope of the pharmaceutical product lifecycle, as
defined by the ICH guidelines, were also discarded. A detailed
description of the used inclusion and exclusion criteria can be
found in the review protocol (Supplementary Information).
Based on this process, the final literature assessment resulted
in 356 publications.
The data was extracted from the records manually via the
evaluation of the full text, when it was available. The selected
publications described 503 application scenarios involving a
wide spectrum of KM tools/solutions for solving pharmaceu-
tical and biotechnological issues. A classification of each KM
tool was performed according to the type of the employed tool
(Table I), managed knowledge source, and the intended
QbD-related objective (as presented in Fig. 1).
To compare the results of this literature review with the
actual perceptions within the biopharmaceutical industry, a
consultation with employees at R&D, management, process
development and regulatory affairs (n= 34) from 17 major
biopharmaceutical organizations was performed via an online
questionnaire. The participants were asked to rank the impor-
tance of the different KM tool classes with respect to applica-
tion towards various QbD-related knowledge sources, the
KM support tools were not included in this questionnaire,
analyzing just the process perspective addressed by the ICH
in its definition for KM. Next, we focused in the four main
functions: acquire, store, use, and distribute knowledge. In
addition, the respondents ranked the applicability of various
QbD-related knowledge sources towards achievement of spe-
cific QbD objectives. According to the area of most expertise
(QbD-related knowledge sources), each participant was asked
to rank the extent of application of the 12 tool classes in their
organization. The following scoring system was used: a score
of (2) for being used, (1) for not being used but considered
useful, (−1) for not considered useful, and (0) for not knowing
the tool. The quantitative results from the literature survey
were normalized versus the actual frequency of the four KM
functions, and used for comparison with the results found
from the industrial questionnaire.
The ethics committee/institutional review board was not
involved in the approval of the study, because no personal
information was collected. The participants were informed
in writing of the scientific purpose and objectives of the study.
In addition, they were asked to consent to the participation.
The participants provided their written consent to participate
in this study. The participant consent was recorded in the
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Table I Functional Classification of KM Tools. Adapted from (7)
Class Definition References
Acquisition
Knowledge and data capture Allows gathering and integration of data, going from
basic paper to software and hardware applications
with functionalities similar to a scientific notebook.
It includes electronic laboratory notebooks, data
logging and best practice reports.
Data integration platforms for R&D production
(9), electronic data capture supporting lab
work (10).
Retrieval Tools used to obtain specific data from structured
sources through use of Query and Answer
platforms or an automated intelligent agent.
Medical information retrieval (11), retrieval in
dynamic data management for chemical
process operations (12)
Data and text mining Applications that explore large volumes of data
to find hidden patterns, creating previously
unknown information from it.
Mining biological molecules structure (13),
visual data mining (14).
Storage
Knowledge and data bases Secondary sources for retrieval at different levels
of abstraction including those with very complex
forms of knowledge. They have several dimensions
to be catalogued in, like syntactic vs. semantic
integration, warehousing vs. federation, declarative vs.
procedural access, generic vs. hard coded and
relational vs. non-relational based data model.
Databases in regulatory reviews (15),
libraries for clinical trials (16),
data repositories for chemical kinetics (17).
Maps, Taxonomies and ontologies While taxonomies and maps are hierarchical
representations of knowledge, ontology defines
and semantically describes the data and information,
being the basis for modeling different forms
of knowledge. They create a common, explicit,
and platform-independent vocabulary that is both
machine accessible and human usable.
Holistic ontologies in pharmaceutical




Visualization Information arrangement that displays a set of
data easily understood by a wide audience.
Graphs, charts and Response Surface
Methods are included.
Visualizing metabolic networks (20),
Response Surface Methodology in
biotechnology (21)
Statistical analyzers Provide quantitative measure of the inherent
variability of a phenomena, assessing the
current state of control and enabling
process improvement.
Chemometrics-based PAT (22),
Integrated statistical platforms to
laboratory management (23)
Intelligent agents Decision support tools that are grounded
in the emulation of skills for reasoning and inference.
Their system is composed by a knowledge base,
an inference engine and an interface for the user.
Intelligent process management in
continuous pharmaceutical operations
(24), intelligent decision support in
pharmaceutical development (25)
Models and simulation Effective integration of knowledge, information,
and assumptions with experimental data in
one unified representation, to predict
outcomes and express relationships.
Modeling in decision making for
drug development (26), multiscale
pharmaceutical mechanistic modeling (27)
Dissemination
Network and web technologies Interfaces and platforms that help to interconnect
resources inside the boundaries of an organization,
exploiting the knowledge within the firm.
Externalization can be achieved through the
use of web technologies (e.g. corporate portals)
aiming to the establishment of virtual organizations.
Pharmaceutical factory monitoring system
based on Ethernet (28), virtual organizations
for pharmaceutical engineering and science (29)
Collaboration Community participation applications like groupware,
collaborative project management software and
electronic conferencing tools, used for accessing
to a firm’s external knowledge or facilitating
research partnerships.
Communities and collaboration in discovery
and development (30), collaborative
drug discovery (31)
Document management systems This tools are found in the interface between storage
and dissemination, they locate documents inside
a clear management police and keep track of
their status and versions.
Modern document management in the
regulatory context (32), electronic document
management (33)
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survey form. In addition, without the consent, the participant
was not allowed to proceed in the survey. No effort was made
to anonymize IP addresses as this information was not visible
to researchers.
Based on the outcome of this analysis, three issues were
detected as having a high priority and were explored further:
1) Knowledge indicators, as the least developed KM tool 2)
Taxonomies and ontologies as the most used KM tool in the
literature and 3)Modeling and simulation, due to its perceived
importance for the creation of design space and potential for
storage of QbD-related product and processes knowledge.
REUNITING THE VIEWPOINTS: KM IN THE
INDUSTRYAND ACADEMIA
Assessment of KM in the Published Literature
Several authors have reported applications of KM principles to-
wards a wide range of pharmaceutical-related tasks. Published
literature included paper that have appeared in international peer
reviewed publications. Categorizing each article in the review
pool according to the previously discussed criteria in terms of
KM tool group, knowledge source, and QbD-related objectives,
allowed the analysis of the state of the art from the perspective of a
life-cycle paradigm. A visualization of the use of the different KM
toolsets within the reviewed academic publications with respect to
the type of knowledge being managed, and the intended QbD-
related objectives is provided in Fig. 2. The matrix reveals the
results from the bibliographic research, categorizing the type of
the tool (columns), the type of the knowledge source (blue rows),
and the intended applications (red rows). The four major
Knowledge sources were identified from the analysis of the
ICH’sQualityGuidelines, being condensed into: Prior knowledge
(biological, chemical, and engineering principles, literature, expe-
rience and information from the development of similar drug
products), pharmaceutical development and innovation (informa-
tion from the use of a scientific approach to understand a product
in its development phase), technology transfer activities (gained
through the transference of product and process knowledge from
development to manufacture and from manufacturing sites), and
manufacturing experience (day-to-day knowledge from routine
commercial manufacturing of the drug product). The final out-
come is colored according to the number of publications, which
allows the identification of over- and under-represented areas. A
comparison of the number of KM tools for solving each of the
QbD-related applications is provided in Fig. 3. In our review,
most of the tools were classified in the BAnalysis^ category. The
categories for knowledge acquisition and storage also contained a
large number of reported tools.
As shown in Fig. 2, some of the reviewed technological solu-
tions are found to be concentrated on using specific sources of
knowledge. For instance, there is a predominance of statistical
analysis tools that use knowledge from manufacturing experi-
ence, such as multivariate data analysis of spectroscopic datasets
(22,49), chemometric tools for implementation of process analyt-
ical technologies (PAT) (23), and Intelligent Agents that supervise
biotechnological processes (50)). Aside from their major role in
manufacturing, these statistical analysis tools are also used for the
management of development information (51). Databases, visu-
alization, retrieval, and data mining tools are focused on prior
knowledge due to their role in the maintenance of knowledge
bases as a core element of a lifecycle-oriented quality systems.
Data capture, collaboration, and document management tools
are linked predominantly to knowledge from development activ-
ities. They perform tasks required for novel data generation and
storage, as it is critical to codify new datasets making them trace-




KM frameworks An organized set of ideas, principles, information,
rules and definitions that configure the structure
of a knowledge management initiative.
Frameworks in process KM (4), a framework
for knowledge-based diagnostic systems in
batch chemical processes (34)
KM models A theoretical representation of the desired or actual
state of a system, making special emphasis on
the knowledge actors, flows, constrains
and relationships
Process model for knowledge management
in plant maintenance (35), structural
model of knowledge management
across borders (36)
KM strategies Plan or direction to achieve the goals of knowledge
management so it can react to uncertain environments.
Strategies for drug knowledge transfer
process in pharmaceutical marketing (37),
strategies to manage knowledge flows
between high-tech firms and universities (38)
KM indicators Figures that represent the level of success for a given
knowledge management activity, aiming to assess its
performance in concordance with a stated goal in
the KM strategy
Measurement scale for knowledge
management in biotechnology (39),
Structural influence index in KM (40)
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been used as tools that guide the flow of information present in
research and development activities. For instance, they have been
used for creating innovation through KM in the pharmaceutical
industry (52,53), for relating intellectual capital and organization-
al performance through intermediate variables, enablers, and
learning flows (54), for presenting technical details of a
workflow-based KM system for manufacturing of liquid-based
drug products (55), for formulating decision analysis frameworks
for risk management (56), and even for developing a KMmodel
to transfer drug related information in pharmaceuticalmarketing
Fig. 2 Distribution of KM applications in the published literature used in various sources of knowledge, as well as in QbD-specific applications. Each number in
the matrix indicates the total number of KM tools found in the scientific literature that fall within the corresponding categorization. The columns of the matrix
indicate the type of KM tools. The first 5 rows (Knowledge sources) show the distribution of KM tools that address knowledge stemming from specific sources of
knowledge as specified by the ICH guidelines for QbD approaches. The lower rows mention the applications of knowledge management tools to specific and
general QbD objectives. Hence, as illustrated in Fig. 1, the knowledge sources (upper rows) are linked by knowledge management tools (columns) to QbD
applications (lower rows).
Fig. 3 Number and type of KM
tools for solving specific QbD-
related applications. KM tools based
on data mining, taxonomies and
intelligent agents are the most used
tools and are mainly based on data
driven algorithms. Mechanistic
approaches such as model and
simulations have an increasing trend
but are less used so far.
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(37). Such diverse applications of KM models demonstrate their
important role within the lifecycle of a pharmaceutical product.
Furthermore, there are some tools that are applied holistically,
not dealing with a single source of knowledge but with a combi-
nation of them. For instance, applications of taxonomies and
ontologies, intelligent agents, network and web technologies
andmodels and simulations can be found across a wide spectrum
of knowledge sources. These technologies will be discussed in
more detail in BIndicators: There is no Management Without
Metrics^, BOntologies: There is no Management Without
Order^ and BRole of Modeling in Facilitating KM^ sections.
Regarding tools that support KM, since KM frameworks and
strategies constitute the basis for a structured KM policy in any
organization, a unified consensus and a standardized set of def-
initions and guidelines for the industry is needed. Currently, the
proposed frameworks have little in common and address the
same issues with an uneven perspective and great dispersion.
Compared to other sources, knowledge from technology
transfer activities (academia to industry or within industry) is
covered less frequently by the reviewed articles. As it will be
shown in later sections, the results of a survey among industrial
representatives revealed that information related to transfer
activities is often considered as sensitive and hence is not
disclosed in the public domain. Also, transfer and validation
activities are located in the interface between development
and manufacturing, and it is often difficult to address this issue
in purely academic settings (7).
Looking at the target of KM activities, enhancement of in-
novation is found to be amajor goal pursued in the investigated
publications. Increasing the body of knowledge is the second
non-specific QbD goal targeted by several authors. Regulatory
flexibility has also been explored through the study of regula-
tory information management systems (57), modeling for
pharmacometrics (58), application of document management
systems (33), use of databases, libraries and reporting templates
(15), and use of information platforms (59).
Use of knowledge and data capture tools is underestimated in
the published literature for the establishment of CQAs and
Design Spaces. While models and simulations are quite
commonly used for the establishment of control strategies in
the industry, most of these applications are not disseminated
publicly and only a few such examples could be located such as
the improvement of manufacturing processes through the
modeling of chemical plants (60) and research and development
through integrative multi-scale modeling frameworks (27).
An Industrial Perspective of KM
For analyzing perceptions within the biopharmaceutical in-
dustry, consultation with employees (n= 34) of 17 major bio-
pharmaceutical organizations was performed via an online
questionnaire. As shown in Fig. 4a, most respondents
belonged to organizations with more than 1000 employees,
and almost half of the respondents indicated to have some
Fig. 4 Results of an online survey conducted among biotechnology professionals. (a) Size of affiliated organizations, the majority is large organizations, but also
SMEs. (b) Existence of KM systems at the corresponding organizations. Only half of the organizations, thereof mainly large organizations, used KM systems. (c)
Geographical location, mainly industrial countries were included in the survey (d) Professional experience with different sources of knowledge, classical fields of
process and manufacturing science are supported by KM tools, while QbD related tasks (e.g. prior knowledge) are less addressed.
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kind of KM system in place in their respective organizations
(Fig. 4b). The majority of respondents indicated to be based in
either the United States or within Europe (Fig. 4c).
Responding to the question of Bwhich knowledge source do
you have the most experience with?^, 46.9% indicated to be
most familiar with knowledge from Bdevelopment studies,^
followed by 34.4% who indicated to be more familiar with
knowledge from Bmanufacturing experience^ (Fig. 4d).
Figure 5 let us to compare the importance rating given by
the industrial respondents to each of the knowledge sources in
the achievement of the main QbD goals; this point of view is
represented in bar plots ranking from 0 to 4.5. Aside each set
of bars, a segmented plot let us see the frequency found in the
literature for specific KM tools used in the same 4 main QbD
goals; the color key corresponds to the same classification of
sources applied in the bar plots. As it was expected, there are
no tools in the literature that manage transfer activities’ knowl-
edge to support the achievement of the QbD goals and there
are no tools using prior knowledge for the establishment of
control strategies. For the definition of the CQAs, if we follow
the importance given by the industry, we should expect a
similar frequency of tools using prior and development knowl-
edge. Instead there is a deficit in development of such tools.
Design space establishment is dominated by tools that manage
knowledge from development, with only a few targeting new
applications for managing information from manufacturing.
Finally, there is a misbalance in the tools targeting develop-
ment of control strategy: while the industrials give a similar
importance score for both the development and manufactur-
ing knowledge in the achievement of this goal, the actual
frequency in the literature prioritizes manufacturing knowl-
edge over the development knowledge by a nearly 1:4 ratio.
Comparison of Academic and Industrial Perspectives
A comparison of the reviewed literature and the results obtain-
ed from the industrial questionnaire was performed, addressing
the relative frequency of the KM tools in the literature (the ratio
of a tool’s usage compared with the use of all kinds of KM
tools), and the relative importance rating defined by the indus-
try (averaging the scores givenwhen the participants were asked
to rate the importance and use of a tool in their organizations).
This exercise allowed us to identify three distinct groups of KM
tools, as shown in Fig. 6. The first group represent the technol-
ogies which are recognized as being modestly important by the
respondents of the survey (centered on the mean), and also
receive a significant amount of attention from the academic
community. These include technologies, such as knowledge
retrieval tools (T2), network and web technologies (T10), data-
bases (T4), and datamining tools (T3). The technologies includ-
ed in Group 2 are ranked as relevant by the industry but not
congruently represented in the literature (e.g. visualization
tools, statistical analyzers, capture tools, and document man-
agement systems). On the other hand, the tools included in
Group 3 were found to be commonly addressed by literature
sources and yet not ranked as important by industrial represen-
tatives (ontologies and intelligent agents).
Group 2 is composed of tools which are widespread and tra-
ditionally accepted for their knowledge management attributes.
The reason for the lack of attention by the scientific community is
Fig. 5 Importance of the knowledge sources for achievement of QbD goals rated by professionals vs. the number of tools in the literature. Comparison of the
importance rating given by the industrial respondents to each of the knowledge sources in the achievement of the main QbD goals to literature, represented in bar
plots ranking from 0 to 4.5. Aside each set of bars, a segmented plot shows the frequency found in the literature for specific KM tools used in the same four main
QbD goals; the color key corresponds to the same classification of sources applied in the bar plots.
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perhaps a lack of interest as a result of their perceived limited
value towards research. However, these primary tools continue
to be relevant, as there is an industrial need for rethinking their
functionalities in the QbD paradigm. For instance, data flow
automation as an enhanced knowledge capture tool, diminishes
manual documentation and the related control activities, boosting
the efficiency up to a 30% for laboratory staff and management
(10). A shift towards extraction of know-how and tacit knowledge
(61) as opposed to the classic explicit data capture approaches also
represent new direction for research in this field. Similarly, visu-
alization tools have recently been enhanced for visual datamining
(14) and interactive hypothesis generation (62). These tools have
also been combined with other KM tools as in the case of
ontology-related semantic graphs for hypothesis generation (63).
The challenge for these classic tools is to be continuously
reinvented according to the demands of data-rich environments
and the complexity of their multivariate relationships.
The tools included in Group 3, perceived as less important
by the industry yet addressed highly by the scientific commu-
nity (consisting of taxonomies and intelligent agents) can be
considered as technologically more demanding. These are
clearly areas for further research to realize potential benefits
that will result from their industrial implementation.
However, the reason for the discrepancy between the rankings
is likely due to a lack of thorough understanding by the indus-
trial respondents of the tools, perhaps as a result of their higher
complexity. Additionally, a contributing factor might be a gap
in the understanding of industrial needs by academic
researchers.
From this analysis, we highlight three tool classes that are
highly valuable for further discussion within the pharmaceu-
tical community. These will be discussed together with few
examples in the later sections.
1- KM indicators appear to be the least developed resource
and have not been applied to any QbD specific goal,
despite being praised in management areas for give direc-
tion to different kind of initiatives (64,65).
2- Taxonomies and ontologies, which are often linked with
artificial intelligence, are recognized by the academic
community as powerful tools for managing knowledge
within the pharmaceutical research field.
3- Simulation and modeling have been explored to a larger
extent due to their connection with QbD implementa-
tion: product and process understanding.Modeling fulfills
the definition of a functional design space, representing an
efficient knowledge summary, which is able to explain the
behavior of a given system on a mechanistic level.
PROMISING KM TOOLS FOR
PHARMACEUTICAL PRODUCTION SYSTEMS
Indicators: There is no Management Without Metrics
An indicator is a quantitative or qualitative measure which pro-
vides information on the status of a system and is a reference for
Fig. 6 Comparison between the relative frequency of a tool reported in the literature and the relative importance rating addressed by the industrial question-
naire. Group 1 represents the technologies which are recognized as being modestly important by the respondents of the survey, and also receive a significant
amount of attention from the academic community. The technologies included in Group 2 are ranked as relevant by the industry but not congruently represented
in the literature. The technologies included in Group 3 are perceived as less important by the industry yet addressed highly by the scientific community. Mean
values are shown as dotted lines. T1: Capture tools, T2: Retrieval tools, T3: Data mining, T4: Data and knowledge bases, T5: Taxonomies and ontologies, T6:
Visualization tools, T7: Statistical analyzers, T8: Intelligent agents, T9: Models and simulation, T10: Network and web technologies, T11: Collaboration tools, and
T12: Document management systems.
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supporting appropriate decision making. They are grounded in
the measurement of performance figures detected as markers of
success or failure for a definite activity or set of activities.
Therefore, delineation of factors that impact an activity’s success
is a critical step for the establishment of indicators. In this direc-
tion, a previous work outlined 32 variables for pharmaceutical
KM systems, underlining seven critical factors: benchmarking
and knowledge structure, organizational culture, information
technology, employee involvement and training, leadership and
commitment of senior management, learning environment and
resource control, and professional training evaluation (46). In the
same field, without focusing on the pharmaceutical industry, the
inclusion of knowledge practices in strategic planning has also
been analyzed (66). The authors weighed product leadership,
customer intimacy, and operational excellence, to discover a di-
rect relation between knowledge and intermediate organization-
al performance metrics.
Once the link to a certain performance measurement is
established, clearer indicators can be generated. An example
of this can be found in the study of individual performance
through the assessment of attributes and actions. Ten individ-
ual knowledge indicators have been proposed, composed by
knowledge stock indicators (education, training, experience,
IT literacy), knowledge flow indicators (business communica-
tions, business process interactions, personal network), knowl-
edge utilization indicators (performance and creativity), and
one indicator related to financial figures (67).
Another approach has been proposed through the use of
patent-based performance metrics to reveal the scientific and
technological components of a pharmaceutical firm’s knowledge
base (considered as its ‘core’ element). The patent’s metrics have
been correlated with four innovative performance variables: the
scope of firm knowledge base, research expenditures, firm size,
and external knowledge flows (68). This can be complemented
with the bigger task of evaluation of the intellectual capital as a
whole. A recent study in this field accounted for human capital
(learning and education, experience and expertise and innova-
tion and creation), structural capital (systems and programs, re-
search and development and intellectual property rights), and
relational capital (strategic alliances, licensing and agreements
and relation and knowledge about partners, suppliers and cus-
tomers). The authors proposed 17 human, 11 structural and 14
relational capital indicators (69). These performance-based indi-
cators have some complications, as measurement of an entire
organization’s KM performance is difficult to assess from the
perspective of process, leadership, culture or technology. Better
efficiency and effectiveness in KM performance can be achieved
through a project-orientated approach (70). The latter is relative-
ly unexplored in the pharmaceutical field.
A firm’s knowledge strategy can also be addressed in three
dimensions: the emphasis on speed of learning (technology
cycle length), emphasis on internal sourcing (R&D spending)
versus external sourcing of knowledge (R&D activities closeness
to basic science), and the development of a broad versus a
narrow knowledge base (through the patent’s dispersion in-
dex) (71). Furthermore, a recent survey has examined how
biotechnology companies placed value on knowledge sources
that supported R&D, including elements such as the existence
of scientific databases, the policies to protect IP, employee
education, and information derived from industry and public
sources (72). Top priority was given to the IP protection,
followed by the firm’s scientific database and employee edu-
cation was ranked third of the knowledge assets.
Ontologies: There is no Management Without Order
Chaos cannot be managed, and knowledge is easily accessed
when it is transferable to information systems. Because of this, a
common, explicit, and platform-independent vocabulary that is
both machine accessible and human usable is needed to stream-
line the generation and flow of knowledge (18). An ontology
defines and semantically describes data and information. This
serves as the basis for modeling different kinds of knowledge,
avoiding difficulties around the organization of related informa-
tion and the lack of open and systematic ways to manage meta-
data (25). Taxonomies (hierarchies of data in classes) and ontol-
ogies (explicit description of classes by their properties) can thus
serve as the spinal cord of the KM systems over which further
knowledge applications like intelligent support engines and data-
bases can be developed.
As a core in many knowledge-based systems, taxonomies and
ontologies exhibit several characteristics needed for the four func-
tions of KM to be integrated, leading to the unification of vocab-
ularies towards the fulfillment of lifecycle initiatives. Therefore,
several authors have extensively studied them in different areas:
risk management (73,74), product formulation, unit operation
model integration (18), determination of CQAs and CPPs (75),
mathematical model storage, use, and solving (19), regulatory
compliance (76), manufacturing execution systems (77) and drug
discovery (78).
Ontologies are also fundamental in intelligent reasoning sys-
tems, which usually possess three components: a knowledge base
where information from a specific process is stored continuously,
an inference engine that makes the reasoning possible, and an
interface that translates the findings to a common language for
the user. The inference engine has a logical component that
generally has an ontological structure and can vary in complex-
ity, coming from single agents to modular systems where agents
interact with one another to achieve individual objectives by
exchanging information, cooperating or negotiating to solve con-
flicts (79).
Role of Modeling in Facilitating KM
Growing manufacturing costs and increased demands for re-
ducing the time and resources required for development of
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production processes have led to an increased interest towards
model-based approaches for optimization of biochemical pro-
cesses. From the viewpoint of KM, process models represent
accumulated expert knowledge generated over years, which
allows the simulation of system behavior in the face of pertur-
bations (27). Dynamic simulations of process models offer a
cost-effective approach for exploring design spaces before sig-
nificant process development is carried out and can be used
from the very earliest development stages through scale-up
and optimization of operating conditions (80). Therefore, pro-
cess models have been widely recognized as a supporting tool
for monitoring, control, and optimization of biochemical pro-
cesses within the QbD paradigm.
Generally, a process model consists of a mathematical rep-
resentation of the interrelationships between process parame-
ters and process outputs or quality attributes. Models can be
developed to describe a variety of operations, ranging from
upstream to downstream unit operations, in addition to inte-
grated models that encompass series of operations (80).
Process models have often been based on mechanistic knowl-
edge about the underlying processes on a physical, chemical,
or biological level. These models, also known as phenomeno-
logical models, not only have the advantage of encompassing
a summary of available knowledge, but also provide value in
planning experiments, or in determining which CPPs need to
be monitored and controlled tightly (81,82). The required
mechanistic knowledge for setting up models has been tradi-
tionally based on experimental observations leading to formu-
lation of hypotheses on a case-by-case basis. The formulation
of a well-regarded mechanistic model of overflow metabolism
in biological organisms serves as an example (83). There is a
clear trend towards development of methods which aid the
identification and testing of various hypotheses in a fast and
reliable manner, so that the time and cost required for setting
up a robust mechanistic model for an unknown system is re-
duced (84). In our review of the available literature, we iden-
tified a gap with respect to KM strategies that support this
aim: supporting mechanistic model development by summa-
rizing existing process knowledge in an ordered manner.
Conversely, data-driven models rely on statistical infer-
ences based on training datasets. While advantageous in cases
where mechanistic process knowledge is scarce; the need for
extensive training datasets is often a limiting factor for the
applicability of such models during initial process develop-
ment stages. While useful for data mining, hypothesis genera-
tion, and analysis of multivariate datasets generated by PAT
instrumentations (22,85), the parameters of statistical models
are more difficult to interpret; therefore, are not as useful as
mechanistic models to serve as a store of available process
knowledge.
In the future, the use of mechanistic models as efficient
knowledge management and storage tools could be enhanced
by combination with other technologies, such as ontologies.
Since, semantic technologies allow for the standardization of a
system’s knowledge content and the readability by machines,
automated generation of mechanistic models based on collec-
tion of hypotheses from multiple actors can be envisioned.
Ontological-modeling approaches, such as OntoMODEL,
have been previously developed (19). This example represents
an ontological tool for management of mathematical models,
model storage, usage, and simulation studies. These ideas are
also explored in the development of applied decision support
systems for pharmaceutical manufacture (86), as well to math-
ematical knowledge modeling to define the processing route
for manufacturing through a guideline’s execution system (87,
88). Currently, there is an opportunity to further explore the
possibilities offered by the combination of ontologies and clas-
sical modelling approaches, as they could play an important
role for knowledge transfer using an elegant and effective
method for information codification.
CONCLUSIONS
Knowledge must be analyzed according to the principles of
quality risk management, prioritizing valuable information in
data-rich environments. This constitutes the foundation of the
QbD philosophy, where knowledge and risk management be-
come the main enablers of a lifecycle approach. RM serves as
a useful approach both for aggregation of information that is
required to perform key QbD related activities such as design
space definition as well as for managing information during
the lifecycle of a commercial product. However, while RM
has been explored in detail due to higher attention by the
regulatory agencies, KM has received relatively scant atten-
tion. As the pharmaceutical industry grows in complexity,
KM has gained a prominent seat, enhancing and being en-
hanced by the QbD initiative as a core technology in a true
pharmaceutical quality system.
A simple yet effective classification of knowledge sources
can be achieved based on their nature and criticality,
reflecting the major sources of knowledge being addressed,
namely information stemming from development activities,
manufacturing experience, and knowledge from technology
transfer activities. Further, KM tools can be catalogued with
respect with themain function they perform: acquisition, anal-
ysis, storage and dissemination. These tools are supported by
knowledge indicators, strategies, models and frameworks.
In our review of existing studies on the topic of KM related
toQbD, we highlight that knowledge from transfer activities is
not sufficiently covered by the current KM tools. However,
there is a predominant use of statistical analyzers for the man-
agement of knowledge from manufacturing activities. On the
other hand, databases, visualization tools, retrieval and data
mining tools are focused on capture of prior knowledge.
Collaboration and document management tools are mainly
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linked to knowledge from development studies. There are
some tools that are applied holistically: taxonomies and ontol-
ogies, intelligent agents, network and web technologies, and
models and simulation. However, taxonomies and intelligent
agents which are highly quoted in literature and relevant in
accelerating bioprocess development and commercialization,
are conversely perceived as less important by the industrial
counterparts. We found major gaps that could help to consol-
idate a true KM-based pharmaceutical quality systems if suf-
ficiently developed: knowledge indicators, ontologies, and a
combination of ontologies and mechanistic modeling
approaches.
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